First human test of Single-Shot gene therapy for ALS begins
Disease control
Recruiting now
This is an early-stage study to check the safety of a new, one-time gene therapy called VTx-002 for people with ALS. It will involve 12 participants who will receive a single injection and be closely monitored for up to 5 years. The main goal is to see if the treatment is safe an…
Phase: PHASE1, PHASE2 • Sponsor: Vector Y Therapeutics • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC